Lab-grown meat startup Vow used a gene from mammoth DNA identical to one in Asian elephants. But their meatball doesn't taste like woolly mammoth.
Chief Medical Officer Taha Kass-Hout and other Amazon scientists gathered last week for the Amazon Machine Learning Conference.
Insider toured the $30 billion genomics giant's San Diego headquarters to learn about Illumina's venture into drug research and diagnostics.
Sangamo Therapeutics has given its first dose of an experimental T-cell therapy in an effort to treat autoimmune diseases, Insider has learned.
A fresh upswing for biotech stock could be on the cards, but being such a broad sector some parts of the market will fare better than others.
Eric Huang told Insider how he planned to make Moderna Genomics a gene-editing leader by 2030. "Moderna doesn't move slowly," he said.
GSK is betting genetics research will play a large role in the future of the $106 billion drugmaking giant.
In an interview with Insider, Regeneron's cofounder said genetics will change the future of medicine and shared how his biotech will lead.
Biotechs upstarts have raised hundreds of millions of dollars to bring ideas from the software industry to drug development.
23andMe started trading on Thursday. Insider analyzed the 323-page regulatory filing made public as part of 23andMe's stock-market debut.
Inside Helix, the genomics company that helped the CDC track the Alpha variant's spread within the US, and where it plans to go from here.
The Vision Fund has made waves in Silicon Valley, but has been quietly investing in biotech companies for years.
China has been stealing data, including DNA files, to advance its economic, security, and foreign-policy goals, the US government says.
Matt Moberg, a fund manager with Franklin Templeton's Equity Group, lays out four megatrends he sees as rich backdrops for investing.
Since Vision Fund I launched in 2017, the Japanese behemoth has backed 11 US healthcare startups, with a focus on biotechnology companies.
Behind Tesla, the third largest holding in the ARKK ETF is CRISPR Therapeutics, a gene editing company that makes up 5.7% of the fund.
Cathie Wood's genomic-innovation ETF has skyrocketed in the past year, but she said it was only scratching the surface of its potential growth.
From immunotherapy to the Affordable Care Act, here's a look at the decade's biggest healthcare developments.
The $1 billion growth fund has made investments in the genomics-testing startup Sophia Genetics and in Andela, which trains software developers.
As humans begin to live longer and more make it to 100, it's going lead to a $610 billion market by 2025, according to analysts at Bank of America.